Zimvie [ZIMV] vs Boston Scientific [BSX] Detailed Stock Comparison

Zimvie Inc.

NASDAQ
Loading...

Boston Scientific Corporation

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Zimvie Inc. wins in 6 metrics, Boston Scientific Corporation wins in 13 metrics, with 0 ties. Boston Scientific Corporation appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Zimvie Inc. Boston Scientific Corporation Better
P/E Ratio (TTM) -20.20 27.49 Boston Scientific Corporation
Price-to-Book Ratio 1.30 4.02 Zimvie Inc.
Debt-to-Equity Ratio 56.82 48.92 Boston Scientific Corporation
PEG Ratio 3.03 0.29 Boston Scientific Corporation
EV/EBITDA 17.09 19.85 Zimvie Inc.
Profit Margin (TTM) -4.39% 17.29% Boston Scientific Corporation
Operating Margin (TTM) 3.33% 21.55% Boston Scientific Corporation
EBITDA Margin (TTM) 3.33% 21.55% Boston Scientific Corporation
Return on Equity -4.76% 11.84% Boston Scientific Corporation
Return on Assets (TTM) 0.51% 6.64% Boston Scientific Corporation
Free Cash Flow (TTM) $7.49M $3.40B Boston Scientific Corporation
1-Year Return 36.91% -52.97% Zimvie Inc.
Price-to-Sales Ratio (TTM) 1.21 4.74 Zimvie Inc.
Enterprise Value $699.90M $107.72B Boston Scientific Corporation
EV/Revenue Ratio 1.58 5.23 Zimvie Inc.
Gross Profit Margin (TTM) 64.55% N/A N/A
Revenue per Share (TTM) $16 $14 Zimvie Inc.
Earnings per Share (Diluted) $-0.69 $2.39 Boston Scientific Corporation
Beta (Stock Volatility) 2.06 0.78 Boston Scientific Corporation
Short % of Float 1.93% 1.58% Boston Scientific Corporation

Zimvie Inc. vs Boston Scientific Corporation Stock Performance Analysis

Loading Price Chart...

ZIMV
BSX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Zimvie Inc.0.00%0.05%0.58%1.23%112.89%103.32%
Boston Scientific Corporation-0.32%-3.98%-11.24%-33.00%-49.28%-50.63%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Zimvie Inc.36.91%131.59%-57.04%-57.04%-57.04%-57.04%
Boston Scientific Corporation-52.97%-13.64%9.04%108.58%590.87%133.50%

Performance & Financial Health Analysis: Zimvie Inc. vs Boston Scientific Corporation

MetricZIMVBSX
Market Information
Market Cap i$535.72M$97.63B
Market Cap CategoryN/ALarge cap
10 Day Avg. Volume i256,32618,916,072
90 Day Avg. Volume i302,28216,730,711
Last Close$18.99$46.76
52 Week Range$8.15 - $19.01$45.99 - $109.50
% from 52W High-0.11%-57.30%
All-Time High$50.40 (Feb 14, 2022)$109.50 (Sep 09, 2025)
% from All-Time High-62.32%-57.30%
Growth Metrics
Quarterly Revenue Growth0.00%0.12%
Quarterly Earnings Growth0.00%0.99%
Financial Health
Profit Margin (TTM) i-0.04%0.17%
Operating Margin (TTM) i0.03%0.22%
Return on Equity (TTM) i-0.05%0.12%
Debt to Equity (MRQ) i56.8248.92
Cash & Liquidity
Book Value per Share (MRQ)$14.64$16.34
Cash per Share (MRQ)$2.49$1.32
Operating Cash Flow (TTM) i$11.97M$4.50B
Levered Free Cash Flow (TTM) i$11.75M$10.53B
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Zimvie Inc. vs Boston Scientific Corporation

MetricZIMV (Nov 10, 2025)BSX (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i-20.2027.49
Forward P/E i28.7717.29
PEG Ratio i3.030.29
Price to Sales (TTM) i1.214.74
Price to Book (MRQ) i1.304.02
Market Capitalization
Market Capitalization i$535.72M$97.63B
Enterprise Value i$699.90M$107.72B
Enterprise Value Metrics
Enterprise to Revenue i1.585.23
Enterprise to EBITDA i17.0919.85
Risk & Other Metrics
Beta i2.060.78
Book Value per Share (MRQ) i$14.64$16.34

Financial Statements Comparison: Zimvie Inc. vs Boston Scientific Corporation

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricZIMV (2024)BSX (2025)
Revenue/Sales i449.75M20.07B
Cost of Goods Sold i162.30M6.22B
COGS % of Revenue i36.1%31.0%
Gross Profit i287.45M13.85B
Gross Margin i63.9%69.0%
Research & Development i26.91M2.05B
Operating Income (EBIT) i-2.10M3.97B
Operating Margin i-0.5%19.8%
EBITDA i48.17M5.33B
EBITDA Margin i10.7%26.6%
Pre-Tax Income i-23.59M3.39B
Pre-Tax Income % of Revenue i-5.2%16.9%
Income Tax i10.24M493.00M
Income Tax % of Revenue i2.3%2.5%
Net Income (Profit) i-25.83M2.89B
Profit Margin i-5.7%14.4%

Balance Sheet & Liquidity Metrics

MetricZIMV (2024)BSX (2025)
Cash & Equivalents i74.97M1.97B
Total Current Assets i257.29M8.79B
Total Current Assets % of Revenue i57.2%43.8%
Total Current Liabilities i133.94M5.44B
Total Current Liabilities % of Revenue i29.8%27.1%
Long-Term Debt i228.67M11.14B
Long-Term Debt % of Revenue i50.8%55.5%
Total Shareholders Equity i381.71M24.47B
Retained Earnings i-466.64M5.57B
Retained Earnings % of Revenue i-103.8%27.8%
Property, Plant & Equipment i00

Cash Flow Statement Comparison

MetricZIMV (2024)BSX (2025)
Operating Cash Flow i33.89M4.50B
Operating Cash Flow % of Revenue i7.5%22.4%
Capital Expenditures i-6.68M-876.00M
Free Cash Flow i7.49M3.40B
FCF Margin i1.7%17.0%
Debt Repayment i-290.00M-2.05B
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricZIMVBSX
Shares Short i531,52523.53M
Short Ratio i0.811.59
Short % of Float i1.93%1.58%
Shares Outstanding i28.20M1.49B
Float Shares i21.66M1.48B
% Held by Insiders i2.73%0.21%
% Held by Institutions i90.96%95.16%
% Held by Public i6.31%4.63%

Dividend Analysis & Yield Comparison: Zimvie Inc. vs Boston Scientific Corporation

MetricZIMVBSX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A